Julie Mchugh Sells Ironwood Pharmaceuticals Shares
Julie Mchugh executed a planned sale of 21,571 Ironwood Pharmaceuticals shares.
Key Points
- Julie Mchugh sold 21,571 shares of Ironwood Pharmaceuticals on June 16, 2026, for approximately $80,459.83.
- Ironwood Pharmaceuticals trades on NasdaqGS under the ticker IRWD, with a market cap of $579.4 million and a P/E ratio of 5.68.
- Analysts from Citizens and Wells Fargo have maintained their ratings, with target prices ranging from $3 to $10.
On June 16, 2026, Julie Mchugh sold 21,571 shares of Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD) in a planned transaction. The shares were sold at an average price of $3.73, totaling approximately $80,459.83.
What Changed in Julie Mchugh's Ironwood Pharmaceuticals Position
Julie Mchugh's recent transaction involved the sale of 21,571 shares of Ironwood Pharmaceuticals. This transaction was part of a pre-planned arrangement, with the shares fetching an average price of $3.73, resulting in a total value of $80,459.83.
Other Institutional Activity in Ironwood Pharmaceuticals
Several institutional investors have also adjusted their positions in Ironwood Pharmaceuticals. BlackRock, Inc. increased its holdings by 578,124 shares, ending with 13,362,930 shares valued at approximately $46.9 million. AQR Capital Management LLC boosted its holdings by 2,811,549 shares, reaching a total of 7,535,080 shares worth about $26.4 million. Conversely, Sarissa Capital Management LP reduced its position by 6,730,800 shares, leaving it with 9,188,635 shares valued at around $32.3 million.
Ironwood Pharmaceuticals Stock Snapshot
Shares of Ironwood Pharmaceuticals (NasdaqGS: IRWD) recently traded at $3.66. The company has a market capitalization of approximately $579.4 million, with a P/E ratio of 5.68 and a forward P/E of 2.44. Its beta is 0.241, indicating lower volatility compared to the market. The stock's 52-week range is between $0.66 and $5.78, with a 50-day moving average of $3.86 and a 200-day moving average of $3.25.
Recent Earnings
Ironwood Pharmaceuticals reported revenue of $361.5 million, with a revenue growth rate of 1.59%. The company achieved a net margin of 28.26%, and its earnings per share (EPS) stood at $0.62. The next earnings announcement is expected on August 6, 2026.
Analysts Set New Price Targets
On February 26, 2026, Citizens maintained a "buy" rating on Ironwood Pharmaceuticals, setting a target price of $10. Wells Fargo has maintained a "hold" rating with a target price of $5 as of January 5, 2026. Analysts have given a consensus target price of $6.10, based on four opinions.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc., headquartered in Boston, Massachusetts, is a biotechnology company specializing in therapies for gastrointestinal and rare diseases. The company markets linaclotide, a treatment for irritable bowel syndrome with constipation, under the LINZESS and CONSTELLA names. Ironwood is also developing treatments for visceral pain and short bowel syndrome. With strategic partnerships with companies like AbbVie and AstraZeneca, Ironwood continues to focus on innovative healthcare solutions.
Bottom Line
Julie Mchugh's planned sale of Ironwood Pharmaceuticals shares is part of routine insider activity. Ironwood Pharmaceuticals, with its focus on gastrointestinal and rare disease treatments, remains a company of interest for investors. Analyst ratings provide a varied outlook on the stock, reflecting its potential and market position.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.